KARS1P1: A Potential Drug Target and Biomarker (G100419558)

Target Name: KARS1P1

NCBI ID: G100419558

KARS1P1

Other Name(s): lysyl-tRNA synthetase 1 pseudogene 1 | Lysyl-tRNA synthetase pseudogene 1 | KARSP1

KARS1P1: A Potential Drug Target and Biomarker

KARLSRCHN K189 and KARLSRCHN K229 are the two most abundant genes in the human proteome, encoding a protein named Kars1p1. Kars1p1 is a 16-kDa protein that plays a critical role in the intracellular signaling pathway known as the TGF-β pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and survival. Kars1p1 has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, Kars1p1 has emerged as a promising drug target and biomarker for a variety of diseases.

The TGF-β pathway is a complex signaling pathway that is activated by the binding of the protein TGF-β to its receptor, which is found in various tissues throughout the body. The TGF-β receptor has four transmembrane伪 chains, which are involved in the regulation of cell growth, differentiation, and survival. The Kars1p1 protein is a key component of the TGF-β pathway, as it is involved in the regulation of the activity of the TGF-β receptor.

Kars1p1 was first identified as a gene that was expressed in various tissues and organs, including brain, heart, liver, and pancreas. It is characterized by the presence of a unique N-terminal domain that is involved in the regulation of the TGF-β receptor. This domain is known as the N-terminal domain, and it is responsible for the interaction between Kars1p1 and the TGF-β receptor.

The N-terminal domain of Kars1p1 is made up of 119 amino acid residues and is located at the protein's cytoplasmic side. It is involved in the regulation of the activity of the TGF-β receptor by interacting with its extracellular domain. This interaction between Kars1p1 and the TGF-β receptor is critical for the regulation of cellular processes, including cell growth, differentiation, and survival.

Kars1p1 has been shown to play a role in the regulation of cellular processes that are important for the development and progression of various diseases. For example, studies have shown that Kars1p1 is involved in the regulation of cell growth and differentiation, and that it plays a role in the development of cancer. Additionally, Kars1p1 has been implicated in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

As a result, Kars1p1 has emerged as a promising drug target and biomarker for a variety of diseases. The development of small molecules that can modulate the activity of Kars1p1 could provide new treatments for diseases that are currently untreated or have limited treatment options. Additionally, the study of Kars1p1's role in the TGF-β pathway could provide new insights into the mechanisms of disease and the potential for targeted therapies.

In conclusion, Kars1p1 is a protein that is involved in the regulation of the TGF-β pathway and has been implicated in the development and progression of various diseases. As a potential drug target and biomarker, Kars1p1 is a promising target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of Kars1p1 in the TGF-β pathway and its potential as a drug target and biomarker.

Protein Name: Lysyl-tRNA Synthetase 1 Pseudogene 1

The "KARS1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KARS1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets